Teva introduces generic painkiller
NORTH WALES, Pa. — Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.
Teva announced the introduction of oxymorphone hydrochloride tablets.
The drug is a generic version of Endo Pharmaceuticals’ Opana and will be available in the 5 mg and 10 mg strengths in bottles of 100 tablets.
GSK tests lupus drug in patients with inflammatory blood vessel disorder
LONDON — GlaxoSmithKline has started a late-stage clinical trial of a drug in patients with an inflammatory disease that affects the blood vessels.
The drug maker announced the start of a phase-3 trial of Benlysta (belimumab) in patients with vasculitis, a condition in which the body’s immune system attacks blood vessels, leading to inflammation, disruption of blood flow and possible damage to the organs. The drug is being tested in patients with a common form of the disease known as anti-neutrophil cytoplasmic antibodies-positive vasculitis.
The Food and Drug Administration originally approved Benlysta in 2011 for treating lupus.
Actavis to market, distribute authorized generic version of Valeant drug; Valeant to co-promote Actavis drug
PARSIPPANY, N.J. — Actavis will market and distribute an authorized generic version of a genital herpes ointment made by Valeant Pharmaceuticals International, the companies said Friday.
The agreement centers around Zovirax, known generically as acyclovir, in the 5% strength. The Food and Drug Administration approved the generic version, made by Mylan, on Wednesday. Financial terms of the deal were not disclosed.
Unlike an FDA-approved generic, an authorized generic is the branded drug marketed under its generic name at a discounted price, usually through a third-party company.
The agreement also gives Valeant the right to co-promote Actavis Specialty Brands’ Cordran Tape (flurandrenolide), a treatment for skin conditions like psoriasis, eczema and contact dermatitis, in the United States.